GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UnicoCell Biomed Co Ltd (TPE:6794) » Definitions » Gross-Profit-to-Asset %

UnicoCell Biomed Co (TPE:6794) Gross-Profit-to-Asset % : 3.82% (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is UnicoCell Biomed Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. UnicoCell Biomed Co's annualized Gross Profit for the quarter that ended in Dec. 2024 was NT$30.08 Mil. UnicoCell Biomed Co's average Total Assets over the quarter that ended in Dec. 2024 was NT$787.19 Mil. Therefore, UnicoCell Biomed Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 3.82%.


UnicoCell Biomed Co Gross-Profit-to-Asset % Historical Data

The historical data trend for UnicoCell Biomed Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UnicoCell Biomed Co Gross-Profit-to-Asset % Chart

UnicoCell Biomed Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial 0.63 1.69 2.30 3.25 2.81

UnicoCell Biomed Co Quarterly Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.48 0.60 1.68 4.46 3.82

Competitive Comparison of UnicoCell Biomed Co's Gross-Profit-to-Asset %

For the Biotechnology subindustry, UnicoCell Biomed Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UnicoCell Biomed Co's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UnicoCell Biomed Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where UnicoCell Biomed Co's Gross-Profit-to-Asset % falls into.


;
;

UnicoCell Biomed Co Gross-Profit-to-Asset % Calculation

UnicoCell Biomed Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=20.57/( (685.929+777.889)/ 2 )
=20.57/731.909
=2.81 %

UnicoCell Biomed Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=30.084/( (796.494+777.889)/ 2 )
=30.084/787.1915
=3.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


UnicoCell Biomed Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of UnicoCell Biomed Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


UnicoCell Biomed Co Business Description

Traded in Other Exchanges
N/A
Address
Minquan East Road, 5th Floor, No. 13-20, Section 6, Neihu District, Taipei, TWN, 11494
UnicoCell Biomed Co Ltd is a biotechnology company. Its main business includes new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D.

UnicoCell Biomed Co Headlines

No Headlines